Automate Your Wheel Strategy on XNCR
With Tiblio's Option Bot, you can configure your own wheel strategy including XNCR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol XNCR
- Rev/Share 2.21
- Book/Share 8.3516
- PB 1.7685
- Debt/Equity 0.3433
- CurrentRatio 5.3407
- ROIC -0.1537
- MktCap 1053441389.0
- FreeCF/Share -1.8957
- PFCF -7.4811
- PE -6.1682
- Debt/Assets 0.2422
- DivYield 0
- ROE -0.2673
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | XNCR | Barclays | -- | Underweight | -- | $6 | Sept. 17, 2025 |
| Downgrade | XNCR | BofA Securities | Buy | Neutral | -- | $12 | Sept. 3, 2025 |
| Initiation | XNCR | William Blair | -- | Outperform | -- | -- | April 21, 2025 |
| Initiation | XNCR | Wells Fargo | -- | Overweight | -- | $37 | Dec. 12, 2024 |
News
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Published: October 21, 2025 by: Business Wire
Sentiment: Neutral
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24 at 1:30 p.m. ET (10:30 a.m. PT) to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma.
Read More
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Published: October 14, 2025 by: Business Wire
Sentiment: Neutral
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the upcoming presentation of initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a bispecific ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with clear cell renal cell carcinoma (ccRCC) in a poster at the AACR-NCI-EORTC Conference on Molecular Targets an.
Read More
Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Xencor (XNCR) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.11 per share a year ago.
Read More
Xencor (XNCR) Upgraded to Buy: Here's Why
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
About Xencor, Inc. (XNCR)
- IPO Date 2013-12-03
- Website https://www.xencor.com
- Industry Biotechnology
- CEO Bassil I. Dahiyat
- Employees 250